Clinical Pharmacology K12 Training Program

项目总结/摘要 在过去的20年里，国会，国立卫生研究院（NIH）和食品和药物管理局（FDA） 美国食品和药物管理局（FDA）已经明确表示，儿童安全的药物治疗是一个高度优先事项。的飞速 随着医疗保健和研究环境的不断变化，关注下一代的培训变得至关重要。 儿科临床药理学领域的一代领导者，他们参与了双手的设计和实施- 在儿童药物研究，以增加新的和有效的治疗儿童的翻译。拟议 辛辛那提儿童儿科临床药理学K12计划旨在为各种 一群初级教师成为儿科临床药理学的下一个领导者。这包括以下方面的培训 儿科临床药理学的原则，以那些谁可能从来没有以前的临床药理学 经验，同时也促进了从奖学金到初级教师到独立调查员的过渡， 曾接受过儿科临床药理学研究员培训的人员。培训计划我们 K12学者在此申请中提出的建议将利用内部存在的优秀研究基础设施， 辛辛那提儿童医院医疗中心和辛辛那提大学学术健康中心， 我们在辛辛那提儿童临床部建立了强大的研究培训活动， 药理学，以及我们部门与其他临床药理学 T32研究中心和全国各地的临床药理学项目。通过我们严格的培训计划， 我们希望学者们能够达到以下五个核心能力：1）基础知识和技能， 药物计量学，2）药物遗传学的基础知识和技能，3）深入了解 发育药理学原理对药物作用和毒性的影响，4）进行研究的能力 各种儿科患者群体，和5）跨学科团队研究的协作技能。的 实现这些核心能力的四个培训支柱将集中在1）研究培训，2）负责 进行研究，3）教学/研究导师和4）通过两者的领导和职业发展 体验式学习和教学课程，包括要获得的知识和技能以及预期成果， 每一个这些领域。预期的学者成果包括描述以下研究的高影响力手稿： 儿科临床药理学，提交独立的K职业发展奖或R奖，交付 在地方论坛和全国会议上就临床药理学主题进行讲座和演讲， 具有在地方和国家一级指导受训人员的经验，并在国家委员会担任领导职务， 临床药理学学会。我们打算有两个初级教师学者任命在任何时候与 预期任用期为2至3年，视外部赠款供资情况而定。该计划将扩大 儿科临床药理学研究者的极少数，他们将推进个性化治疗 来改善儿童的健康状况。

PROJECT SUMMARY/ABSTRACT During the past 20 years, Congress, the National Institutes of Health (NIH), and the Food and Drug Administration (FDA) have made it clear that safe drug therapy for children is a high priority. With the rapidly changing health care and research environments, it has become essential to focus on the training of the next generation of leaders in Pediatric Clinical Pharmacology who are involved in the design and conduct of hands- on drug studies in children to augment the translation of new and effective therapies for children. The proposed Cincinnati Children’s Pediatric Clinical Pharmacology K12 program aims to provide the resources for a diverse group of junior faculty to become the next leaders in Pediatric Clinical Pharmacology. This includes training in the principles of Pediatric Clinical Pharmacology to those who may never had previous clinical pharmacology experience while also facilitating the transition from fellowship to junior faculty to independent investigator for those who have had previous fellowship training in Pediatric Clinical Pharmacology. The training program we propose in this application for K12 Scholars will leverage the outstanding research infrastructure that exists within Cincinnati Children’s Hospital Medical Center and the University of Cincinnati Academic Health Center, the strong research training activities that we have built within the Cincinnati Children’s Division of Clinical Pharmacology, and the robust collaborations that our Division has developed with other Clinical Pharmacology T32 sites and Clinical Pharmacology programs throughout the nation. Through our rigorous training program, we expect Scholars to achieve the following five core competencies: 1) Foundational Knowledge and Skill in Pharmacometrics, 2) Foundational Knowledge and Skills in Pharmacogenetics, 3) In-depth Understanding of the Impact of Developmental Pharmacology Principles on Drug Action and Toxicity, 4) Ability to Conduct Studies in a Variety of Pediatric Patient Populations, and 5) Collaborative Skills in Interdisciplinary Team Research. The four pillars of training to achieve these core competencies will be focused on 1) research training, 2) responsible conduct of research, 3) teaching/research mentorship and 4) leadership and career development through both experiential learning and didactic courses with knowledge and skills to be attained and expected outcomes in each of these areas. Intended Scholar outcomes include high impact manuscripts describing research in Pediatric Clinical Pharmacology, submission of independent K career development awards or R awards, delivery of lectures and presentations on clinical pharmacology topics in local forums and national conferences, experience in mentoring trainees locally and nationally, and leadership positions in national committees in Clinical Pharmacology societies. We intend to have two junior faculty Scholars appointed at any time with the anticipated appointments being 2 to 3 years, depending on external grant funding. This program will expand the critically small pool of Pediatric Clinical Pharmacology investigators who will advance personalized therapeutics in pediatrics to improve the health outcomes of children.